Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paradime-TIR Trial
jRCTs051220061Completed
- Sponsor
- Not applicable
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Not applicable. Primary endpoint: Change in Time in Range (TIR) by CGM in imeglimin group. Started Jul 2022; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220061.